Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist

被引：0
|
作者：
Akihito Ogasawara
Kei Ogawa
Ryosuke Ide
Yuka Ikenaga
Chie Fukunaga
Satoshi Nakayama
Minoru Tsuda
机构：
[1] Mitsubishi Tanabe Pharma Corporation,
[2] Mitsubishi Tanabe Pharma Corporation,undefined
来源：
European Journal of Clinical Pharmacology | 2023年 / 79卷
关键词：
Erythropoietic protoporphyria; Dersimelagon; First-in human; Melanin density; X-linked protoporphyria;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：801 / 813
页数：12
相关论文
共 50 条
  • [1] Results from a first-in-human study of dersimelagon, an investigational oral selective MC1R agonist
    Ogasawara, Akihito
    Ogawa, Kei
    Ide, Ryosuke
    Ikenaga, Yuka
    Fukunaga, Chie
    Nakayama, Satoshi
    Tsuda, Minoru
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 79 (06) : 801 - 813
  • [2] Erythropoietic Protoporphyria: Phase 2 Clinical Trial Results Evaluating the Safety and Effectiveness of Dersimelagon (MT-7117), an Oral MC1R Agonist
    Balwani, Manisha
    Bonkovsky, Herbert L.
    Belongie, Kirstine J.
    Anderson, Karl E.
    Takahashi, Fumihiro
    Irizarry, Antonio
    Amster, Mark
    Bissell, D. Montgomery
    Wang, Bruce
    Hazan, Lydie
    Parker, Charles J.
    Cordasco, Edward
    Levy, Cynthia
    Desnick, Robert J.
    BLOOD, 2020, 136
  • [3] Absorption, metabolism, and excretion of [14C]dersimelagon, an investigational oral selective melanocortin 1 receptor agonist, in preclinical species and healthy volunteers
    Tsuda, Minoru
    Ogawa, Kei
    Endou, Tadashi
    Goto, Takahiro
    Ogasawara, Yuko
    Ogasawara, Akihito
    PHARMACOLOGY RESEARCH & PERSPECTIVES, 2023, 11 (03): : e01084
  • [4] Novel α-MSH/γ-MSH hybrid analogues that lead to selective ligands for the human MC1R and human MC3R
    Cai, Minying
    Stankova, Magda
    Cabello, Christopher
    Decot, Bridgette
    Mayorov, Alexander
    Trivedi, Dev
    Hruby, Victor J.
    PEPTIDE REVOLUTION: GENOMICS, PROTEOMICS & THERAPEUTICS, 2004, : 651 - 652
  • [5] Safety Outcomes From a First-in-Human Study of a Novel Investigational Monoclonal Antibody, REGN5381, an Agonist to the Natriuretic Peptide Receptor 1
    Kithcart, Aaron P.
    Dunn, Michael E.
    Hoon, Jan De
    Botermans, Wouter
    Karnik, Satyajit
    Burczynski, Michael E.
    Zheng, Wenjun
    Rankin, Andrew J.
    Herman, Gary
    Olenchock, Benjamin
    CIRCULATION, 2023, 148
  • [6] A polymorphism study of the human Agouti gene and its association with MC1R
    Voisey, J
    Box, NF
    van Daal, A
    PIGMENT CELL RESEARCH, 2001, 14 (04): : 264 - 267
  • [7] MC1R variants and melanoma risk: First study on Melan-Cohort
    Soufir, N.
    Miss, L. Bagait
    Miss, C. Oudin
    Wolkenstein, P.
    Descamps, V.
    Dupin, N.
    Lebbe, C.
    Basset-Seguin, N.
    Saiag, P.
    Grandchamp, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [8] Results From the First-in-Human Study With Ozanimod, a Novel, Selective Sphingosine-1-Phosphate Receptor Modulator
    Tran, Jonathan Q.
    Hartung, Jeffrey P.
    Peach, Robert J.
    Boehm, Marcus F.
    Rosen, Hugh
    Smith, Heather
    Brooks, Jennifer L.
    Timony, Gregg A.
    Olson, Allan D.
    Gujrathi, Sheila
    Frohna, Paul A.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (08): : 988 - 996
  • [9] Pharmacokinetics and pharmacodynamics of mibavademab (a leptin receptor agonist): Results from a first-in-human phase I study
    Gewitz, Andrew
    Mendell, Jeanne
    Wang, Yuhuan
    Harris, Charles
    Olenchock, Benjamin A.
    Podgrabinska, Simona
    Zheng, Wenjun
    Zhao, An
    Pan, Hao
    Vanhoutte, Frederic
    Davis, John D.
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (04):
  • [10] Safety and efficacy results from the first-in-human study of the oral MEK 1/2 inhibitor GSK1120212
    Infante, J. R.
    Fecher, L. A.
    Nallapareddy, S.
    Gordon, M. S.
    Flaherty, K. T.
    Cox, D. S.
    DeMarini, D. J.
    Morris, S. R.
    Burris, H. A.
    Messersmith, W. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345